BibTex format
@article{Kura:2023:10.1098/rstb.2022.0277,
author = {Kura, K and Milton, P and Hamley, JID and Walker, M and Bakajika, DK and Kanza, EM and Opoku, NO and Howard, H and Nigo, MM and Asare, S and Olipoh, G and Attah, SK and Mambandu, GL and Kennedy, KK and Kataliko, K and Mumbere, M and Halleux, CM and Hopkins, A and Kuesel, AC and Kinrade, S and Basáñez, M-G},
doi = {10.1098/rstb.2022.0277},
journal = {Philosophical Transactions of the Royal Society B: Biological Sciences},
pages = {1--11},
title = {Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?},
url = {http://dx.doi.org/10.1098/rstb.2022.0277},
volume = {378},
year = {2023}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Epidemiological and modelling studies suggest that elimination of Onchocerca volvulus transmission (EoT) throughout Africa may not be achievable with annual mass drug administration (MDA) of ivermectin alone, particularly in areas of high endemicity and vector density. Single-dose Phase II and III clinical trials demonstrated moxidectin's superiority over ivermectin for prolonged clearance of O. volvulus microfilariae. We used the stochastic, individual-based EPIONCHO-IBM model to compare the probabilities of reaching EoT between ivermectin and moxidectin MDA for a range of endemicity levels (30 to 70% baseline microfilarial prevalence), treatment frequencies (annual and biannual) and therapeutic coverage/adherence values (65 and 80% of total population, with, respectively, 5 and 1% of systematic non-adherence). EPIONCHO-IBM's projections indicate that biannual (six-monthly) moxidectin MDA can reduce by half the number of years necessary to achieve EoT in mesoendemic areas and might be the only strategy that can achieve EoT in hyperendemic areas. Data needed to improve modelling projections include (i) the effect of repeated annual and biannual moxidectin treatment; (ii) inter- and intra-individual variation in response to successive treatments with moxidectin or ivermectin; (iii) the effect of moxidectin and ivermectin treatment on L3 development into adult worms; and (iv) patterns of adherence to moxidectin and ivermectin MDA.
AU - Kura,K
AU - Milton,P
AU - Hamley,JID
AU - Walker,M
AU - Bakajika,DK
AU - Kanza,EM
AU - Opoku,NO
AU - Howard,H
AU - Nigo,MM
AU - Asare,S
AU - Olipoh,G
AU - Attah,SK
AU - Mambandu,GL
AU - Kennedy,KK
AU - Kataliko,K
AU - Mumbere,M
AU - Halleux,CM
AU - Hopkins,A
AU - Kuesel,AC
AU - Kinrade,S
AU - Basáñez,M-G
DO - 10.1098/rstb.2022.0277
EP - 11
PY - 2023///
SN - 0962-8436
SP - 1
TI - Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?
T2 - Philosophical Transactions of the Royal Society B: Biological Sciences
UR - http://dx.doi.org/10.1098/rstb.2022.0277
UR - https://royalsocietypublishing.org/doi/full/10.1098/rstb.2022.0277
VL - 378
ER -